logo
logo

Eikon Therapeutics Announces $517.8 Million Series B Raise And Expansion Of Executive Leadership Team

Jan 06, 2022•over 3 years ago

Amount Raised

$518 Million

Round Type

series b

HaywardHealth Care

Description

Eikon Therapeutics, Inc., a pioneer in the application of live-cell super-resolution microscopy to drug discovery, today announced that it has closed a $517.8 million Series B financing. Since its founding two years ago, Eikon Therapeutics has raised more than $668 million to advance its mission of inventing new therapies that address grievous illness.

Company Information

Company

Eikon Therapeutics

Location

Hayward, California, United States

About

Eikon Therapeutics is a drug discovery and development company. Our proprietary platform leverages Nobel Prize-winning super-resolution microscopy, advanced engineering, and automation with the goal of bringing important new medicines to patients suffering from grievous illness. Scientists at Eikon measure the real-time movement of individual proteins in living cells to develop differentiated therapeutics. Eikon is based in Hayward, California and can be found online via our website or on Twitter or LinkedIn.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech